| Quantity | 5 mg, 10 mg | 500 µ, g, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg | 100 µ, g, 500 µ, g, 1 mg, 5 mg | 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | 1 mg, 5 mg, 10 mg |
| Description | Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a KD of 3.39 µM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1[1] | ACTH (7-38) (human) is the 7-38 fragment of human ACTH (1-39). human ACTH (1-39), known as a corticotropin inhibitory peptide (CIP), is an antagonist of the ACTH receptor and has no any corticosteroid activity[1] | Charybdotoxin TFA, a 37-amino acid peptide, is a K+ channel blocker[1] | Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide acetate inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide acetate can inhibit oxidative stress, Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide acetate inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide acetate can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide acetate can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis[1][2][3][4][5][6]... Read More | pTH (39-84) (human) is a parathyroid hormone (PTH) C-terminal fragment. pTH (39-84) (human) stimulates osteoclast formation[1] |